Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

Recurrent Glioblastoma Clinical Trial

Official title: A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI

Status Completed

Clinical Trial Summary

This research study is exploring how the blood vessels in the participant's tumor change from treatment with bevacizumab, and how these changes affect the way their tumor absorbs temozolomide (TMZ).

The pilot part of this study is to evaluate the use of [11C] temozolomide PET (TMZ-PET) scans and MRI scans to tell investigators more about how standard treatment with bevacizumab affects the blood vessels in the participant's tumor, and how these changes affect the way the participant's tumor absorbs temozolomide. "Investigational" means that the role of TMZ-PET scans is still being studied and that research doctors are trying to find out more about it.

Bevacizumab is approved by the U.S. Food and Drug Administration for use in people with the participant's type of cancer. It works by blocking signals on a specific protein called vascular endothelial growth hormone (VEGF), which plays a role in promoting the growth of spread of tumor blood vessels. Bevacizumab is an "anti-VEGF' agent because it is designed to slow the growth of the participant's cancer.

Since anti-VEGF agents also affect normal blood vessels in the brain, they can inhibit the way other drugs used in combination with bevacizumab are delivered to the tumor. Researchers are looking for how bevacizumab affects delivery of chemotherapy, in this case temozolomide.

In PET scans, a radioactive substance is injected into the body. The scanning machine finds the radioactive substance, which tends to go to cancer cells.

For the PET scans in this research study, the investigators are using a radioactive substance called [11C] temozolomide, which is chemically identical to the prescription drug TMZ. TMZ is FDA approved as a chemotherapeutic agent in cancer but [11C] temozolomide is an investigational agent.

In this research study, participants will receive standard treatment with bevacizumab and oral temozolomide as well as standard MRI scans. In addition, participants will undergo TMZ-PET scans before and after treatment with bevacizumab. The first TMZ-PET scan will occur 7-13 days after starting treatment with oral temozolomide but before beginning treatment with bevacizumab, day 1 after starting treatment with bevacizumab and 1 month after starting bevacizumab. TMZ-PET scans will be given at the same time as a vascular MRI, which will evaluate the changes in tumor blood flow, blood volume, and how receptive blood vessels are while also measuring how much TMZ is in the brain.

Clinical Trial Description

Before the research starts (screening): After signing the consent form, the participant will be asked to undergo some screening tests or procedures to find out if they can be in the research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that the participant does not take part in the research study. If the participant has had some of these tests or procedures recently, they may or may not have to be repeated.

• A medical history, which includes questions about the participant's health, current medications, and any allergies.

• Physical Exam including measuring the participant's height, weight, and vital signs

• Performance status, which evaluates how the participant is able to carry on with your usual activities.

• Blood tests.

• Blood pregnancy test for women of childbearing potential

• Urine test.

If these tests show that the participant is eligible to participate in the research study, the participant will begin the study treatment. If the participant does not meet the eligibility criteria, the participant will not be able to participate in this research study.

After the screening procedures confirm that the participant is eligible to participate in the research study:

Please note that this study does not add any additional treatment to participants with your type of cancer. There will be no change in your treatment with bevacizumab and daily temozolomide based on the results of any procedures or tests carried out as a part of the study.

Before each set of scans the participant will have the following tests and procedures:

• Routine blood tests to check the participant's overall health

• Creatinine clearance blood test to check for proper kidney function

• Blood pregnancy test for women of childbearing potential

After the participant have been taking oral TMZ for 7-13 days, the participant will have:

• An assessment of their tumor by DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans and PET (Positron Emission Tomography) scan

MRI-PET Scan Procedure:

The participant will have their scans performed in Charlestown, MA at the Martinos Center. The participant will be injected with two separate intravenous (IV) lines for:

• [11C] temozolomide for PET scan and a contrast dye for the MRI scan

• Drawing blood to assess the radioactivity of [11C] temozolomide [11C] temozolomide PET Scans (TMZ PET Scan):

• The PET scan will take approximately 90 minutes. The participant will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.

MRI Scan:

• MRI scans will last about 60-75 minutes. This will occur at the same time as the PET scan. The participant will be injected with contrast dye twice during the MRI scan.

The MR-PET scan(s) will be performed again on Day 1 after initiation of bevacizumab (or Day 15 after initiation of temozolomide) and Day 30 after initiation of bevacizumab (on Day 45 after initiation of temozolomide).

Blood samples will be collected during both scans in order to measure how your blood vessels are processing the radiotracer [11C] temozolomide and how well it is being delivered to the tumor tissue. Blood samples will be drawn 2.5, 5, 10, 20, 40, 60, 75, and 90 minutes after the [11C] temozolomide injection.

The participant will be assessed for side effects via clinic visit or phone call about 24 hours after each of the visits above.

• Planned Follow-up: The investigators would like to call the participant every 3 months for three years after their second MR-PET scan to see how they are doing and if the participant is experiencing any side effects. If the participant was removed from the study due to an unacceptable side effect, the participant will be followed until it has been resolved. ;

Related Conditions & MeSH terms

• Glioblastoma
• Recurrent Glioblastoma

• NCT number: NCT01987830
• Study type: Interventional
• Source: Massachusetts General Hospital
• Status: Completed
• Phase: N/A
• Start date: November 2013
• Completion date: April 2019